Digital therapeutics (DTx) have the ability to fill gaps in care for people and their families across the world. As a new category of medicine, one of the first barriers is the integration into the traditional healthcare system so that patients can receive access in a way that is convenient and consistent for them. This effort takes significant collaboration amongst diverse parties across the complex healthcare system in the United States.
These parties include policymakers from governing bodies, clinician and provider systems, health plans, pharmacies, DTx product manufacturers, and patients. However, there are many healthcare partners working behind the scenes to make it all work including pricing compendias and EHR vendors. Over the last two years, DTA has worked with these stakeholders in close partnership with NCPDP to address identified pain points in the workflows.
A critical barrier identified is understanding the payment pathways as they impact each stakeholder downstream. Through the generous support of the NCPDP Foundation, DTA was awarded a grant to research how DTx products would be reimbursed. Following the reimbursement workflows, we were able to finish the outline by addressing the distribution of the products into the hands of patients and their families.
We are proud of the efforts of our member task groups and other engaged stakeholders as we present this fourth and final DTx Integration & Workflow Report. While there are recommendations to improve the aspects of the healthcare system, we have been able to achieve our goal to outline how to integrate digital therapeutic products into the standard practice of care.
View final report (September 2024): DTx Integration and Workflow Report